Rituximab and Chemotherapy Followed by Ibritumomab Tiuxetan as Treatment for Low Grade Follicular Non-Hodgkin's Lymphoma

This study has been completed.
Sponsor:
Collaborator:
Biogen Idec
Information provided by:
SCRI Development Innovations, LLC
ClinicalTrials.gov Identifier:
NCT00193440
First received: September 12, 2005
Last updated: December 29, 2010
Last verified: December 2010